Table 11.6f

Immunosuppression Use for Maintenance by Regimen

One Year Following Transplantation, 1996 to 2005

Recipients with Heart Transplants

  Transplant Year
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Transplants 2,343 2,293 2,348 2,188 2,199 2,202 2,155 2,057 2,015 2,125
Functioning Graft at 1 Year PostTx 1,931 1,876 1,939 1,780 1,820 1,851 1,819 1,752 1,749 1,797
With Maintenance Use Recorded at 1 Year PostTx 168 222 1,083 1,724 1,755 1,830 1,783 1,715 1,740 1,782
--- + MMF/MPA 0.6% 0.9% 0.2% 0.1% 0.2% 0.1% 0.2% 0.4% 0.2% 0.1%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.2% 0.2% 0.7%
--- + MMF/MPA + Steroids 0.0% 0.5% 0.6% 0.5% 0.8% 0.5% 0.6% 0.3% 0.6% 0.4%
--- + OtherAntimet 0.0% 0.0% 0.2% 0.2% 0.2% 0.1% 0.0% 0.1% 0.0% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.1%
--- + OtherAntimet + Steroids 0.6% 0.0% 0.1% 0.1% 0.1% 0.2% 0.1% 0.1% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.5% 0.0% 0.0% 0.0% 0.1% 0.0% 0.2% 0.0% 0.0%
--- + Siro/Evero + Steroids 0.0% 0.0% 0.0% 0.1% 0.2% 0.4% 0.3% 0.2% 0.1% 0.2%
--- + Steroids 3.0% 4.5% 5.4% 2.0% 2.2% 3.4% 0.4% 0.2% 0.4% 0.1%
CyA 0.6% 0.9% 1.0% 0.9% 1.3% 0.8% 0.8% 0.8% 0.3% 0.3%
CyA + MMF/MPA 2.4% 5.9% 7.6% 8.5% 9.7% 9.0% 8.6% 8.5% 8.3% 7.7%
CyA + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0% 0.1% 0.1%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% 0.5% 0.1% 0.2%
CyA + MMF/MPA + Steroids 21.4% 26.6% 36.4% 35.1% 41.0% 33.5% 27.7% 24.9% 23.6% 20.8%
CyA + OtherAntimet 7.7% 3.2% 3.6% 3.3% 2.3% 1.6% 2.4% 1.2% 1.4% 0.7%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.1% 0.0%
CyA + OtherAntimet + Steroids 32.1% 23.4% 15.1% 11.3% 6.6% 4.6% 3.2% 2.0% 2.8% 1.0%
CyA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.1% 0.2% 0.8% 0.8% 0.5% 0.2%
CyA + Siro/Evero + Steroids 0.0% 0.0% 0.2% 1.2% 1.3% 0.8% 1.2% 2.5% 1.0% 0.6%
CyA + Steroids 4.8% 4.5% 2.6% 4.9% 3.6% 1.9% 1.9% 1.9% 0.9% 1.5%
Tac 1.8% 2.3% 1.2% 1.3% 1.1% 0.7% 1.6% 1.3% 1.2% 2.3%
Tac + MMF/MPA 0.6% 0.5% 2.2% 2.8% 3.4% 6.9% 6.3% 10.4% 10.7% 15.2%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2%
Tac + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.3% 0.2% 0.3% 0.3%
Tac + MMF/MPA + Steroids 2.4% 8.6% 13.9% 14.6% 16.9% 21.2% 25.0% 25.7% 32.2% 33.6%
Tac + OtherAntimet 1.2% 0.0% 0.5% 0.9% 0.9% 0.9% 1.1% 1.0% 1.3% 1.1%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.1% 0.0% 0.1% 0.0%
Tac + OtherAntimet + Steroids 3.6% 6.3% 4.2% 3.4% 1.9% 2.6% 1.9% 2.0% 1.6% 1.3%
Tac + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.2% 0.2% 1.3% 1.5% 0.9% 1.5%
Tac + Siro/Evero + Steroids 0.0% 0.0% 0.3% 0.5% 1.0% 2.9% 4.5% 4.4% 2.2% 2.1%
Tac + Steroids 2.4% 3.2% 2.4% 2.3% 2.3% 4.3% 3.5% 3.0% 2.6% 2.8%
Other Regimen 14.9% 8.6% 2.6% 5.9% 2.7% 3.1% 6.0% 5.5% 6.3% 5.1%


Source: OPTN/SRTR Data as of May 1, 2007.

Percentages are calculated based on the total number of patients with maintenance use at one year following transplantation. They sum to 100 percent for each column.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.